Table 1 Baseline demographics
CP-868,596 plus docetaxel ( n =39) | CP-868,596 plus docetaxel plus axitinib ( n =9) | Overall ( n =48) | |
|---|---|---|---|
Age in years, median (range) | 55.0 (25–78) | 59.0 (31–74) | 57 (25–78) |
Gender, n (%) | |||
Male | 28 (71.8) | 9 (100) | 37 (77.1) |
Female | 11 (28.2) | 0 | 11 (22.9) |
ECOG performance status, n (%) | |||
0 | 22 (56.4) | 1 (11.1) | 23 (47.9) |
1 | 16 (41.0) | 7 (77.8) | 23 (47.9) |
2 | 1 (2.6) | 1 (11.1) | 2 (4.2) |
Primary diagnosis, n | |||
NSCLC | 7 | 3 | 10 |
Prostate cancer | 5 | 1 | 6 |
Oesophageal carcinoma | 4 | 1 | 5 |
Ewing's sarcoma | 3 | 0 | 3 |
Sarcoma | 5 | 0 | 5 |
Small cell lung cancer | 3 | 0 | 2 |
Colorectal cancer | 3 | 0 | 3 |
Other | 9 | 4 | 14 |
Prior cancer therapy | |||
Radiotherapy | 27 (69.2) | 5 (55.6) | 32 (66.7) |
Surgery | 24 (61.5) | 5 (55.6) | 29 (60.4) |
Chemotherapy | 38 (97.4) | 9 (100) | 47 (97.9) |
1 prior regimen | 16 (41.0) | 5 (55.6) | 21 (43.8) |
2 prior regimens | 9 (23.1) | 3 (33.3) | 12 (25.0) |
⩾3 prior regimens | 13 (33.3) | 1 (11.1) | 14 (29.2) |
Hormonal therapy | 7 (17.9) | 1 (11.1) | 8 (16.7) |
Other | 4 (10.3) | 1 (11.1) | 5 (10.4) |
